From NDTV
Center-Right Owned by Adani Group (AMG Media)Ajanta Pharma Q2 Review: Stock Rally Limits Upside Despite Robust Performance, Says Systematix
What each side is saying
One outlet's own words from each side of the spectrum. Quoted, not summarised.
-
right · 1 outlet
The brokerage incorporates Ajanta Pharma's quarterly performance into its estimates and expect India to remain a key growth driver, supported by sustained outperformance against IPM, while factoring in normalisation in Africa institutional business.
— NDTV
RSS excerpt
The brokerage incorporates Ajanta Pharma's quarterly performance into its estimates and expect India to remain a key growth driver, supported by sustained outperformance against IPM, while factoring in normalisation in Africa institutional business.